Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

PCI Comparable to CABG in Left Main Coronary Disease: Meta-analysis

Michael O'Riordan

December 14, 2017

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

Todd Neale

November 16, 2017

News Industry News

New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

November 14, 2017

News Conference News AHA 2017

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

Michael O'Riordan

November 13, 2017

News Conference News AHA 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Michael O'Riordan

November 12, 2017

Presentation TCT 2017

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Pascal Vranckx

November 01, 2017

Presentation TCT 2017

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Renato D. Lopes

November 01, 2017

Presentation TCT 2017

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

Presenter: Robert A. Harrington, Kurt Huber, Michael D. Ezekowitz

November 01, 2017

Presentation TCT 2017

When and Which Antiplatelet Agent Should Be Dropped When Using Oral Anticoagulant Therapy?

Presenter: Robert A. Harrington, Kurt Huber, Roxana Mehran

November 01, 2017

Presentation TCT 2017

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: Robert A. Harrington, Kurt Huber, Michelle O'Donoghue

November 01, 2017

Presentation TCT 2017

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

Presenter: Robert A. Harrington, Kurt Huber, Didier Carrié

November 01, 2017

Presentation TCT 2017

What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants

Presenter: Robert A. Harrington, Kurt Huber, Freek W.A. Verheugt

November 01, 2017

Presentation TCT 2017

TCT 80: Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation and Flutter After PCI or CABG for Left Main Disease: Analysis From the EXCEL Trial

Presenter: Davide Capodanno, Tullio Palmerini, Ioanna Kosmidou

October 31, 2017

Presentation TCT 2017

Atrial Fibrillation and PCI/ACS: NOACs, Dual Therapy, and Triple Therapy

Presenter: Thomas H. Maloney, C. Michael Gibson

October 30, 2017

News Conference News TCT 2017

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Michael O'Riordan

October 30, 2017

News Daily News

No Anticoagulation Benefit, High Bleeding Risk Seen in Patients With Secondary A-fib

Michael O'Riordan

September 29, 2017

News Conference News ESC 2017

LAACS: Surgical Closure of the Left Atrial Appendage Shows Promise

Shelley Wood

September 04, 2017

Advertisement

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

PCI Comparable to CABG in Left Main Coronary Disease: Meta-analysis

RE-DUAL PCI Findings Consistent Across Key Subgroups

New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

When and Which Antiplatelet Agent Should Be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants

TCT 80: Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation and Flutter After PCI or CABG for Left Main Disease: Analysis From the EXCEL Trial

Atrial Fibrillation and PCI/ACS: NOACs, Dual Therapy, and Triple Therapy

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

No Anticoagulation Benefit, High Bleeding Risk Seen in Patients With Secondary A-fib

LAACS: Surgical Closure of the Left Atrial Appendage Shows Promise

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content